[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Sources::
Editorial Board::
Executive Members::
Articles Archive::
Instruction to Authors::
Peer-Review::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 23, Issue 3 (10-2021) ::
J Gorgan Univ Med Sci 2021, 23(3): 47-51 Back to browse issues page
Evaluation of the Correlation between the Alteration of Specific Biochemical Indicators levels in the Early Stages of Colorectal Cancer
Roya Abbasinatajomrani1 , Durdi Qujeq * 2, Reza Hajihosseini3 , Vahid Hosseini4
1- Ph.D Candidate in Biochemistry, Department of Biology, Payame Noor University, Tehran, Iran.
2- Professor of Biochemistry, Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran. , dqujeq@gmail.com
3- Professor of Biochemistry, Department of Biology, Payame Noor University, Tehran, Iran.
4- Associate Professor of Gastroenterology and Hepatology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Abstract:   (2796 Views)
Background and Objective: Colorectal cancer is one of the most common cancers and considered to be leading causes of cancer death in the world. One of the problems with this type of cancer is its inability to be detected in early stage. The aim of present study was to evaluate the correlation between the serum levels of Fucosyltransferase-4 and galactin-3 in patients with early-stage of colorectal cancer.
Methods: This case-control study was done on 40 patients with early stages of colorectal cancer and 40 healthy subjects. ELISA method was used to measure the serum levels of Fucosyltransferase-4 and galactin-3. To examine the correlation between the variables, correlation test and Pearson correlation coefficient index were used.
Results: Fucosyltransferase-4 and galactin-3 levels were higher in patients with early-stage of colorectal cancer compared to healthy subjects. This difference was not significant. In patients with colorectal cancer, there was a significant relationship between the level of Fucosyltransferase-4 and galactin-3 (r=0.71, P=0.01).
Conclusion: Simultaneous measurement of Fucosyltransferase-4 and galactin-3 is useful in identifying early-stage of colorectal cancer as a non-invasive laboratory method.
Keywords: Colorectal Neoplasms [MeSH], Fucosyltransferase-4 , Galactin-3
Article ID: Vol23-39
Full-Text [PDF 483 kb]   (11481 Downloads)    
Type of Study: Original Articles | Subject: Biochemistry
References
1. Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed Pharmacother. 2017 Mar; 87: 8-19. DOI: 10.1016/j.biopha.2016.12.064 [DOI] [PubMed]
2. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primers. 2015 Nov; 1: 15065. DOI: 10.1038/nrdp.2015.65 [DOI] [PubMed]
3. Janbabaei G, Hedayatizadeh-Omran A, Alizadeh-Navaei R, Moradi S, Ahmadi A, Rashidi Alashti M, et al. An epidemiological study on patients with colorectal cancer admitted to one referral center in north of Iran from 2006 to 2015. WCRJ. 2017; 4(1): e841. DOI: 10.32113/wcrj_20173_841 [View at Publisher] [DOI]
4. Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal. 2014 Jan; 87: 1-11. DOI: 10.1016/j.jpba.2013.08.041 [DOI] [PubMed]
5. Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov. 2004 Oct; 3(10): 863-73. DOI: 10.1038/nrd1521 [DOI] [PubMed]
6. Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, et al. The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev. 2015 Jul; 29(4): 269-79. DOI: 10.1016/j.blre.2015.01.003 [DOI] [PubMed]
7. Li Y, Sun Z, Liu B, Shan Y, Zhao L, Jia L. Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. Cell Death Dis. 2017 Jun; 8(6): e2892. DOI: 10.1038/cddis.2017.281 [DOI] [PubMed]
8. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta. 2002 Sep; 1572(2-3): 263-73. DOI: 10.1016/s0304-4165(02)00313-6 [DOI] [PubMed]
9. Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016 Mar; 1863(3): 427-37. DOI: 10.1016/j.bbamcr.2015.08.008 [DOI] [PubMed]
10. Barrow H, Rhodes JM, Yu LG. The role of galectins in colorectal cancer progression. Int J Cancer. 2011 Jul; 129(1): 1-8. DOI: 10.1002/ijc.25945 [DOI] [PubMed]
11. Yan X, Lin Y, Liu S, Aziz F, Yan Q. Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer. Biomed Pharmacother. 2015 Mar; 70: 299-304. DOI: 10.1016/j.biopha.2014.12.048 [DOI] [PubMed]
12. 12. Muinelo-Romay L, Vázquez-Martín C, Villar-Portela S, Cuevas E, Gil-Martín E, Fernández-Briera A. Expression and enzyme activity of alpha(1,6)fucosyltransferase in human colorectal cancer. Int J Cancer. 2008 Aug; 123(3): 641-46. DOI: 10.1002/ijc.23521 [DOI] [PubMed]
13. Muinelo-Romay L, Villar-Portela S, Cuevas Alvarez E, Gil-Martín E, Fernández-Briera A. α(1,6)Fucosyltransferase expression is an independent prognostic factor for disease-free survival in colorectal carcinoma. Hum Pathol. 2011 Nov; 42(11): 1740-50. DOI: 10.1016/j.humpath.2011.01.021 [DOI] [PubMed]
14. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000 Apr; 6(4): 1389-93. [PubMed]
15. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, Baba H, et al. Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer. Anticancer Res. 2005 Jul-Aug; 25(4): 3117-21. [PubMed]
16. Abbasi Natajomrani R, Qujeq D, Hajihosseini R, Hosseini V. Serum Lipid Profile and Steroid Hormone Levels in Patients With Colorectal Cancer. Hormozgan Med J. 2021; 25(1): 9-13. DOI: 10.5812/hmj.102085 [View at Publisher] [DOI]
17. Abbasinatajomrani R, Qujeq D, Hosseini V, Hajihosseini R. Evaluation of L-fucose and Sialic Acid Levels in Patients With Colorectal Cancer and Control Subject. Res Mol Med (RMM). 2020; 8(3): 147-52. DOI: 10.32598/rmm.8.3.609.7 [View at Publisher] [DOI]
18. Mahmoodi A, Qujeq D, Danesh doust D, Karimi M. Determination of Serum Survivin for Prognostic Role in Esophageal Cancer. J Res Appl Basic Med Sci. 2020; 6(1): 9-13. [View at Publisher]
19. Aghcheli K, Parsian H, Qujeq D, Talebi M, Mosapour A, Khalilipour E, et al. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. Eur J Intern Med. 2012 Jan; 23(1): 58-64. DOI: 10.1016/j.ejim.2011.07.018 [DOI] [PubMed]
Send email to the article author


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbasinatajomrani R, Qujeq D, Hajihosseini R, Hosseini V. Evaluation of the Correlation between the Alteration of Specific Biochemical Indicators levels in the Early Stages of Colorectal Cancer. J Gorgan Univ Med Sci 2021; 23 (3) :47-51
URL: http://goums.ac.ir/journal/article-1-3800-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 23, Issue 3 (10-2021) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 36 queries by YEKTAWEB 4652